Celcuity (CELC) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 06, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38207
Entity Registrant Name	CELCUITY INC.
Entity Central Index Key	0001603454
Entity Tax Identification Number	82-2863566
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	16305 36th Avenue North; Suite 100
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55446
City Area Code	(763)
Local Phone Number	392-0767
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	CELC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,203,156

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 25,759,887	$ 24,571,557
Investments	108,180,417	144,015,954
Other current assets	7,771,131	6,603,026
Total current assets	141,711,435	175,190,537
Property and equipment, net	223,378	260,294
Operating lease right-of-use assets	449,368	246,266
Total Assets	142,384,181	175,697,097
Current Liabilities:
Accounts payable	5,634,806	2,627,076
Finance lease liabilities		2,449
Operating lease liabilities	188,100	191,749
Accrued expenses	6,887,136	4,060,280
Total current liabilities	12,710,042	6,881,554
Operating lease liabilities	270,925	61,002
Note payable, non-current	36,506,774	34,983,074
Total Liabilities	49,487,741	41,925,630
Commitments and Contingencies (Note 5)
Stockholders’ Equity:
Preferred stock, $0.001 par value: 2,500,000 shares authorized; 1,060,873 and 1,120,873 shares issued and outstanding as of September 30, 2023 and December 31, 2022	1,061	1,121
Common stock, $0.001 par value: 65,000,000 shares authorized as of September 30, 2023 and December 31, 2022, respectively; 22,369,393 and 21,667,250 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	22,369	21,667
Additional paid-in capital	234,100,541	230,045,566
Accumulated deficit	(141,227,531)	(96,296,887)
Total Stockholders’ Equity	92,896,440	133,771,467
Total Liabilities and Stockholders’ Equity	$ 142,384,181	$ 175,697,097

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,500,000	2,500,000
Preferred stock, shares issued	1,060,873	1,120,873
Preferred stock, shares outstanding	1,060,873	1,120,873
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	22,369,393	21,667,250
Common stock, shares outstanding	22,369,393	21,667,250

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 17,488,236	$ 9,621,505	$ 42,512,811	$ 24,685,505
General and administrative	1,409,801	1,022,050	3,988,248	3,066,382
Total operating expenses	18,898,037	10,643,555	46,501,059	27,751,887
Loss from operations	(18,898,037)	(10,643,555)	(46,501,059)	(27,751,887)
Other income (expense)
Interest expense	(1,372,132)	(537,661)	(3,929,140)	(1,428,108)
Interest income	1,865,629	287,495	5,499,555	391,301
Other income (expense), net	493,497	(250,166)	1,570,415	(1,036,807)
Net loss before income taxes	(18,404,540)	(10,893,721)	(44,930,644)	(28,788,694)
Income tax benefits
Net loss	$ (18,404,540)	$ (10,893,721)	$ (44,930,644)	$ (28,788,694)
Net loss per share, basic	$ (0.83)	$ (0.75)	$ (2.05)	$ (1.95)
Net loss per share, diluted	$ (0.83)	$ (0.75)	$ (2.05)	$ (1.95)
Weighted average common shares outstanding, basic	22,117,626	14,938,224	21,920,147	14,928,727
Weighted average common shares outstanding, diluted	22,117,626	14,938,224	21,920,147	14,928,727

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 14,919		$ 124,622,405	$ (55,926,847)	$ 68,710,477
Beginning balance, shares at Dec. 31, 2021	14,918,887
Stock-based compensation			756,271		756,271
Exercise of common stock options, net of shares withheld for exercise price	$ 1		7,413		7,414
Exercise of common stock options, net of shares withheld for exercise price, shares	1,415
Net loss				(7,934,447)	(7,934,447)
Ending balance, value at Mar. 31, 2022	$ 14,920		125,386,089	(63,861,294)	61,539,715
Ending balance, shares at Mar. 31, 2022	14,920,302
Beginning balance, value at Dec. 31, 2021	$ 14,919		124,622,405	(55,926,847)	68,710,477
Beginning balance, shares at Dec. 31, 2021	14,918,887
Net loss					(28,788,694)
Ending balance, value at Sep. 30, 2022	$ 14,943		128,225,939	(84,715,541)	43,525,341
Ending balance, shares at Sep. 30, 2022	14,942,958
Beginning balance, value at Mar. 31, 2022	$ 14,920		125,386,089	(63,861,294)	61,539,715
Beginning balance, shares at Mar. 31, 2022	14,920,302
Stock-based compensation	$ 3		1,519,456		1,519,459
Stock-based compensation, shares	3,273
Exercise of common stock options, net of shares withheld for exercise price	$ 2		9,540		9,542
Exercise of common stock options, net of shares withheld for exercise price, shares	1,871
Net loss				(9,960,526)	(9,960,526)
Employee stock purchases	$ 16		80,525		80,541
Employee stock purchases, shares	15,888
Ending balance, value at Jun. 30, 2022	$ 14,941		126,995,610	(73,821,820)	53,188,731
Ending balance, shares at Jun. 30, 2022	14,941,334
Stock-based compensation			1,223,054		1,223,054
Stock-based compensation, shares	250
Exercise of common stock options, net of shares withheld for exercise price	$ 2		7,275		7,277
Exercise of common stock options, net of shares withheld for exercise price, shares	1,374
Net loss				(10,893,721)	(10,893,721)
Ending balance, value at Sep. 30, 2022	$ 14,943		128,225,939	(84,715,541)	43,525,341
Ending balance, shares at Sep. 30, 2022	14,942,958
Beginning balance, value at Dec. 31, 2022	$ 21,667	$ 1,121	230,045,566	(96,296,887)	133,771,467
Beginning balance, shares at Dec. 31, 2022	21,667,250	1,120,873
Stock-based compensation			1,273,282		1,273,282
Stock-based compensation, shares
Exercise of common stock options, net of shares withheld for exercise price	$ 24		127,898		127,922
Exercise of common stock options, net of shares withheld for exercise price, shares	24,122
Conversion of preferred to common stock	$ 250	$ (25)	(225)
Conversion of preferred to common stock, shares	250,000	(25,000)
Issuance costs associated with private placement offering			(7,486)		(7,486)
Net loss				(11,938,417)	(11,938,417)
Ending balance, value at Mar. 31, 2023	$ 21,941	$ 1,096	231,439,035	(108,235,304)	123,226,768
Ending balance, shares at Mar. 31, 2023	21,941,372	1,095,873
Beginning balance, value at Dec. 31, 2022	$ 21,667	$ 1,121	230,045,566	(96,296,887)	133,771,467
Beginning balance, shares at Dec. 31, 2022	21,667,250	1,120,873
Net loss					(44,930,644)
Ending balance, value at Sep. 30, 2023	$ 22,369	$ 1,061	234,100,541	(141,227,531)	92,896,440
Ending balance, shares at Sep. 30, 2023	22,369,393	1,060,873
Beginning balance, value at Mar. 31, 2023	$ 21,941	$ 1,096	231,439,035	(108,235,304)	123,226,768
Beginning balance, shares at Mar. 31, 2023	21,941,372	1,095,873
Stock-based compensation	$ 2		1,276,980		1,276,982
Stock-based compensation, shares	1,958
Exercise of common stock options, net of shares withheld for exercise price	$ 22		113,618		113,640
Exercise of common stock options, net of shares withheld for exercise price, shares	21,086
Conversion of preferred to common stock	$ 100	$ (10)	(90)
Conversion of preferred to common stock, shares	100,000	(10,000)
Net loss				(14,587,687)	(14,587,687)
Employee stock purchases	$ 17		102,621		102,638
Employee stock purchases, shares	17,477
Ending balance, value at Jun. 30, 2023	$ 22,082	$ 1,086	232,932,164	(122,822,991)	110,132,341
Ending balance, shares at Jun. 30, 2023	22,081,893	1,085,873
Stock-based compensation			1,108,637		1,108,637
Exercise of common stock options, net of shares withheld for exercise price	$ 37		59,965		60,002
Exercise of common stock options, net of shares withheld for exercise price, shares	37,500
Conversion of preferred to common stock	$ 250	$ (25)	(225)
Conversion of preferred to common stock, shares	250,000	(25,000)
Net loss				(18,404,540)	(18,404,540)
Ending balance, value at Sep. 30, 2023	$ 22,369	$ 1,061	$ 234,100,541	$ (141,227,531)	$ 92,896,440
Ending balance, shares at Sep. 30, 2023	22,369,393	1,060,873

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (44,930,644)	$ (28,788,694)
Adjustments to reconcile net loss to net cash used for operations:
Depreciation	114,824	161,981
Stock-based compensation	3,658,902	3,498,784
Amortization of debt issuance costs and discount	177,939	284,184
Payment-in-Kind interest	1,345,760	311,764
Non-cash operating lease, net	3,171	(2,791)
Change in accrued interest income	(439,331)
Changes in operating assets and liabilities:
Other current assets	(1,065,732)	(5,817,737)
Accounts payable	3,031,923	1,553,176
Accrued expenses	2,826,856	2,270,422
Net cash used for operating activities	(35,276,332)	(26,528,911)
Cash flows from investing activities:
Proceeds from maturities of investments	221,054,402
Purchases of investments	(184,779,534)
Purchases of property and equipment	(64,945)	(46,724)
Net cash provided by (used for) investing activities	36,209,923	(46,724)
Cash flows from financing activities:
Proceeds from exercise of employee stock options	285,564	24,233
Proceeds from employee stock purchases	102,638	80,541
Payments for secondary registration statement costs	(128,298)	(318,897)
Payments for debt issuance costs	(2,716)	(8,463)
Payments for finance leases	(2,449)	(4,384)
Net cash provided by (used for) financing activities	254,739	(226,970)
Net change in cash and cash equivalents	1,188,330	(26,802,605)
Cash and cash equivalents:
Beginning of period	24,571,557	84,286,381
End of period	25,759,887	57,483,776
Supplemental disclosure of cash flow information:
Interest paid	2,405,441	832,161
Supplemental disclosures of non-cash investing and financing activities:
Offering and registration statement costs included in accounts payable	13,865	11,230
Deferred financing costs and offering and registration statement costs included in accrued expenses		205,000
Property and equipment included in accounts payable	$ 12,961	$ 104,818

Organization

Organization	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Nature of Business Celcuity Inc., a Delaware corporation (the “Company”), is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is expected to be initiated in the first quarter of 2024. The company’s CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based in Minnesota. The Company has not generated any revenues to date.

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (“U.S. GAAP”). The balance sheet at December 31, 2022 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and the related footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. Accounting Estimates Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs. Risks and Uncertainties The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests and initial drug product, gedatolisib, the clinical and commercial success of gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition. Clinical Trial Costs The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company’s research and development expenses. The Company primarily relies on a compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid assets and accrued liabilities. To date, the company believes utilization of third-party reports most accurately reflects expenses incurred. As the current VIKTORIA-1 Phase 3 trial ramps up site activation and patient enrollment, the Company’s estimated expenses in future periods and actual services performed may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes to the Company’s prepaid assets or accrued expenses could materially affect the Company’s results of operations. Recently Adopted Accounting Pronouncements In June 2016 and related amendments, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments – Credit Losses (Topic 326). This guidance changes the methodology to be used to measure credit losses for certain financial instruments and financial assets. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The Company adopted this standard effective January 1, 2023. The adoption of the standard did not have a material impact on the Company’s consolidated financial statements.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Common Share	3. Net Loss Per Common Share Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the preferred stock, options, warrants, and restricted stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share is the same. For the three and nine months ended September 30, 2023 and 2022, potentially dilutive securities excluded from the computations of diluted weighted-average shares outstanding were preferred stock on an as-if-converted to common stock basis of 10,608,730 zero 2,702,629 1,919,114 7,266,102 309,652 1,958 3,273

Investments

Investments	9 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
Investments	4. Investments Debt securities for which the Company has the positive intent and ability to hold to maturity are classified as held-to-maturity and reported at historical cost adjusted for amortization of premiums and accretion of discounts. Expected credit losses, if any, are recorded through the establishment of an allowance for credit losses. All of the Company’s investment securities are U.S. Treasury and agencies securities that are guaranteed or otherwise supported by the United States government and have no history of credit losses. Accordingly, the Company does not expect to incur any credit losses on investment securities and has allowance for credit losses recorded for these securities. The following table summarizes the Company’s held-to-maturity investment securities at amortized cost as of September 30, 2023 and December 31, 2022: Schedule of Investment Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value September 30, 2023 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value U.S. Treasury Bills $ 108,180,417 $ 5,138 $ - $ 108,185,555 Total $ 108,180,417 $ 5,138 $ - $ 108,185,555 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value December 31, 2022 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Governmental Agency Securities $ 46,230,893 $ 29,517 $ - $ 46,260,410 U.S. Treasury Bills 97,785,061 41,639 - 97,826,700 Total $ 144,015,954 $ 71,156 $ - $ 144,087,110 The fair value of the Company’s held-to-maturity debt securities is determined based upon inputs, other than the quoted prices in active markets, that are observable either directly or indirectly and are classified as level 2 fair value instruments.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments	5. Commitments Operating Lease The Company leases its corporate space in Minneapolis, Minnesota, with an operating lease in place through April 30, 2026. The lease provides for monthly rent, real estate taxes, and operating expenses. Rent expense is recorded on a straight-line basis over the lease term. In March 2023, the Company signed the fourth amendment to extend this lease through April 30, 2026. This amendment provides for monthly rent, real estate taxes and operating expenses. The Company recorded an incremental $ 355,578 Clinical Research Studies The Company enters into contracts in the normal course of business to conduct research and development programs internally and through third parties that include, among others, arrangements with vendors, consultants, CMO’s, and CRO’s. The Company currently has four Phase 2 clinical trial agreements in place to evaluate targeted therapies selected with one of our CELsignia tests. Timing of milestone payments related to the Phase 2 clinical trials are uncertain and the contracts generally provide for termination following a certain period after notice, therefore the Company believes that non-cancelable obligations under the agreements are not material. The Company also has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib. In conjunction with the license agreement, the Company continued a Phase 1b study – B2151009 related to gedatolisib. These patients subsequently transitioned to an Expanded Access study – CELC-G-001. Contracts related to the Expanded Access study, are generally based on time and material. In addition, contracts related to the Company’s Phase 3 (VIKTORIA-1) and Phase 1b/2 (CELC-G-201) clinical trials are generally cancelable with reasonable notice within 120 days and the Company’s obligations under these contracts are primarily based on services performed through termination dates plus certain cancelation charges, if any, as defined in each of the respective agreements. In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties. As of September 30, 2023, the Company had two material non-cancelable contractual commitments with respect to these arrangements, which totaled approximately $ 2.3

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Stockholders’ Equity	6. Stockholders’ Equity Capital Stock At December 31, 2022, the Company’s authorized capital stock consisted of 65,000,000 .001 21,667,250 2,500,000 .001 1,120,873 On March 31, 2023, one of the Company’s preferred shareholders elected to convert 25,000 250,0000 5.75 On June 29, 2023, one of the Company’s preferred shareholders elected to convert 10,000 100,0000 5.75 On September 21, 2023, one of the Company’s preferred shareholders elected to convert 25,000 250,0000 5.75 At September 30, 2023, the Company’s authorized capital stock consisted of 65,000,000 22,369,393 2,500,000 1,850,000 1,060,873 no

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation The following table summarizes the activity for all stock options outstanding for the nine months ended September 30: Schedule of Stock Options Activity 2023 2022 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Options outstanding at beginning of year 1,976,586 $ 6.34 1,315,321 $ 11.97 Granted 874,548 10.13 720,047 7.19 Exercised (82,708 ) 3.65 (4,660 ) 5.20 Forfeited (65,797 ) 7.45 (111,594 ) 10.86 Balance at September 30 2,702,629 $ 7.63 1,919,114 $ 6.08 Options exercisable at September 30: 1,440,231 $ 6.26 882,215 $ 5.92 Weighted Average Grant Date Fair Value for options granted during the period: $ 7.09 $ 4.87 The following table summarizes additional information about stock options outstanding and exercisable at September 30, 2023: Schedule of Stock Options Outstanding and Exercisable Options Outstanding Options Exercisable Options Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Options Exercisable Weighted Average Exercise Price Aggregate Intrinsic Value 2,702,629 8.09 $ 7.63 $ 5,355,467 1,440,231 $ 6.26 $ 4,470,641 The Company recognized stock-based compensation expense for stock options of $ 1,065,568 1,162,751 3,516,180 3,329,969 776,324 5.50 30,188 49,088 107,490 477,431 190,000 311,000 13.44 15,773 21,778 49,617 75,562 114,000 203,750 5.10 3,041 7,681 16,975 30,897 3,000 The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions for the nine months ended September 30: Schedule of Assumptions for Fair Value of Equity-based Awards 2023 2022 Risk-free interest rate 3.41 4.61 1.68 3.93 Expected volatility 78.0 79.8 76.2 79.6 Expected life (years) 5.25 6.08 5.29 6.25 Expected dividend yield 0 % 0 % The inputs for the Black-Scholes valuation model require management’s significant assumptions. Prior to the Company’s initial public offering, the price per share of common stock was determined by the Company’s board based on recent prices of common stock sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated based on historical volatility information of peer companies that are publicly available in combination with the Company’s calculated volatility since being publicly traded. All assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection with the agreements would also be cancelled. The Company had 1,958 3,273 0 250 4,903 7,245 13,597 36,686 The Company initially reserved a maximum of 750,000 102,998 149,189 216,673 increase automatically on January 1 of each year from 2024 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31, subject to the board’s discretion to reduce the amount of the increase in any particular year. 500,000 1,000,000 1,500,000 1,147,899 Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows: Schedule of Unrecognized Compensation Cost 2023 $ 1,177,419 2023 $ 1,177,419 2024 3,679,163 2025 2,465,972 2026 1,515,642 2027 635,575 Total estimated compensation cost to be recognized $ 9,473,771 The Company recognized stock-based compensation expense related to its employee stock purchase plan of $ 38,167 53,058 129,125 132,129 100,000 51,499 74,594 108,337 number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31. 283,008 The Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30: Schedule of Stock-based Compensation Expense 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Stock-based compensation expense in operating expenses: Research and development $ 660,706 $ 676,524 $ 1,954,689 $ 1,937,707 General and administrative 447,931 546,530 1,704,213 1,561,077 Total $ 1,108,637 $ 1,223,054 $ 3,658,902 $ 3,498,784

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	8. Debt On April 8, 2021, the Company entered into a loan and security agreement (the “Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”) in its capacity as Collateral Agent and sole Lender. On August 9, 2022, the Company amended the Loan Agreement. Under the amended Loan Agreement, Innovatus, as Lender, has agreed to loan up to $ 75 50 35 15 20 Long-term debt consisted of the following at September 30, 2023 and December 31, 2022: Schedule of Long-term Debt September 30, 2023 December 31, 2022 Note payable $ 35,000,000 $ 35,000,000 Add: PIK interest (added to principal) 2,100,835 755,075 Less: unamortized debt issuance costs (540,392 ) (707,001 ) Less: unamortized debt discount (53,669 ) (65,000 ) Total long-term debt $ 36,506,774 $ 34,983,074 Future principal payments, including the incurred PIK interest, are as follows: Schedule of Long Term Debt Future Principal Payments Years Ending December 31, 2025 $ 13,912,813 2026 18,550,418 2027 4,637,604 Total $ 37,100,835

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events On October 18, 2023, the Company entered into a securities purchase agreement with certain investors (the “Investors”) pursuant to which the Company agreed to sell to the Investors in a private placement (the “Private Placement”) pre-funded warrants (the “Warrants”) to purchase up to 5,747,787 0.001 8.699 0.001 The closing of the Private Placement occurred on October 20, 2023 and resulted in gross proceeds to the Company of approximately $ 50 In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company has agreed to file, no later than 30 days following the Closing Date of the Private Placement, a registration statement covering the resale by the Investors of the shares issued or issuable upon exercise or exchange of the Warrants (as defined more specifically in the Registration Rights Agreement, the “Registrable Securities”). In the event that a registration statement covering the Registrable Securities is not filed with the SEC on or prior to the filing deadline as set forth in the Registration Rights Agreement, or is not declared effective within the timeframe provided therein, or if certain other circumstances occur, as described in the Registration Rights Agreement, that prevent the Investors from selling securities pursuant to the registration statement, the Company has agreed to make pro rata payments to each holder as liquidated damages in an amount equal to 1.0 6.0 On October 13, 2023, one of the Company’s preferred shareholders elected to convert 181,739 1,817,390 5.75

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, as permitted by Article 10, the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the United States (“U.S. GAAP”). The balance sheet at December 31, 2022 was derived from the audited financial statements at that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022 and the related footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.
Accounting Estimates	Accounting Estimates Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests and initial drug product, gedatolisib, the clinical and commercial success of gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.
Clinical Trial Costs	Clinical Trial Costs The Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers, which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company’s research and development expenses. The Company primarily relies on a compilation of progress reports from third-party service providers, including the respective invoicing, to record actual expenses, along with determining changes to prepaid assets and accrued liabilities. To date, the company believes utilization of third-party reports most accurately reflects expenses incurred. As the current VIKTORIA-1 Phase 3 trial ramps up site activation and patient enrollment, the Company’s estimated expenses in future periods and actual services performed may vary from these estimates, and these estimates may become more significant. Changes in these estimates that result in material changes to the Company’s prepaid assets or accrued expenses could materially affect the Company’s results of operations.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016 and related amendments, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments – Credit Losses (Topic 326). This guidance changes the methodology to be used to measure credit losses for certain financial instruments and financial assets. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. The Company adopted this standard effective January 1, 2023. The adoption of the standard did not have a material impact on the Company’s consolidated financial statements.

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, All Other Investments [Abstract]
Schedule of Investment	The following table summarizes the Company’s held-to-maturity investment securities at amortized cost as of September 30, 2023 and December 31, 2022: Schedule of Investment Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value September 30, 2023 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value U.S. Treasury Bills $ 108,180,417 $ 5,138 $ - $ 108,185,555 Total $ 108,180,417 $ 5,138 $ - $ 108,185,555 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value December 31, 2022 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Governmental Agency Securities $ 46,230,893 $ 29,517 $ - $ 46,260,410 U.S. Treasury Bills 97,785,061 41,639 - 97,826,700 Total $ 144,015,954 $ 71,156 $ - $ 144,087,110

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Activity	The following table summarizes the activity for all stock options outstanding for the nine months ended September 30: Schedule of Stock Options Activity 2023 2022 Shares Weighted Average Exercise Price Shares Weighted Average Exercise Price Options outstanding at beginning of year 1,976,586 $ 6.34 1,315,321 $ 11.97 Granted 874,548 10.13 720,047 7.19 Exercised (82,708 ) 3.65 (4,660 ) 5.20 Forfeited (65,797 ) 7.45 (111,594 ) 10.86 Balance at September 30 2,702,629 $ 7.63 1,919,114 $ 6.08 Options exercisable at September 30: 1,440,231 $ 6.26 882,215 $ 5.92 Weighted Average Grant Date Fair Value for options granted during the period: $ 7.09 $ 4.87
Schedule of Stock Options Outstanding and Exercisable	The following table summarizes additional information about stock options outstanding and exercisable at September 30, 2023: Schedule of Stock Options Outstanding and Exercisable Options Outstanding Options Exercisable Options Outstanding Weighted Average Remaining Contractual Life Weighted Average Exercise Price Aggregate Intrinsic Value Options Exercisable Weighted Average Exercise Price Aggregate Intrinsic Value 2,702,629 8.09 $ 7.63 $ 5,355,467 1,440,231 $ 6.26 $ 4,470,641
Schedule of Assumptions for Fair Value of Equity-based Awards	The Black-Scholes option-pricing model was used to estimate the fair value of equity-based awards with the following weighted-average assumptions for the nine months ended September 30: Schedule of Assumptions for Fair Value of Equity-based Awards 2023 2022 Risk-free interest rate 3.41 4.61 1.68 3.93 Expected volatility 78.0 79.8 76.2 79.6 Expected life (years) 5.25 6.08 5.29 6.25 Expected dividend yield 0 % 0 %
Schedule of Unrecognized Compensation Cost	Total unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows: Schedule of Unrecognized Compensation Cost 2023 $ 1,177,419 2023 $ 1,177,419 2024 3,679,163 2025 2,465,972 2026 1,515,642 2027 635,575 Total estimated compensation cost to be recognized $ 9,473,771
Schedule of Stock-based Compensation Expense	The Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30: Schedule of Stock-based Compensation Expense 2023 2022 2023 2022 Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Stock-based compensation expense in operating expenses: Research and development $ 660,706 $ 676,524 $ 1,954,689 $ 1,937,707 General and administrative 447,931 546,530 1,704,213 1,561,077 Total $ 1,108,637 $ 1,223,054 $ 3,658,902 $ 3,498,784

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consisted of the following at September 30, 2023 and December 31, 2022: Schedule of Long-term Debt September 30, 2023 December 31, 2022 Note payable $ 35,000,000 $ 35,000,000 Add: PIK interest (added to principal) 2,100,835 755,075 Less: unamortized debt issuance costs (540,392 ) (707,001 ) Less: unamortized debt discount (53,669 ) (65,000 ) Total long-term debt $ 36,506,774 $ 34,983,074
Schedule of Long Term Debt Future Principal Payments	Future principal payments, including the incurred PIK interest, are as follows: Schedule of Long Term Debt Future Principal Payments Years Ending December 31, 2025 $ 13,912,813 2026 18,550,418 2027 4,637,604 Total $ 37,100,835

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,702,629	1,919,114	2,702,629	1,919,114
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,266,102	309,652	7,266,102	309,652
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,958	3,273	1,958	3,273
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	10,608,730	0	10,608,730	0

Schedule of Investment (Details

Schedule of Investment (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost, as Adjusted	$ 108,180,417	$ 144,015,954
Gross Unrealized Holding Gains	5,138	71,156
Gross Unrealized Holding Losses
Estimated Fair Value	108,185,555	144,087,110
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost, as Adjusted	108,180,417	97,785,061
Gross Unrealized Holding Gains	5,138	41,639
Gross Unrealized Holding Losses
Estimated Fair Value	$ 108,185,555	97,826,700
US Government Agencies Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost, as Adjusted		46,230,893
Gross Unrealized Holding Gains		29,517
Gross Unrealized Holding Losses
Estimated Fair Value		$ 46,260,410

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	1 Months Ended
	Mar. 31, 2023	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Increase in operating ROU asset and lease liability	$ 355,578
Non-cancelable contractual commitment		$ 2,300,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)				9 Months Ended
	Sep. 21, 2023	Jun. 29, 2023	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized				65,000,000	65,000,000
Common stock, par or stated value per share				$ 0.001	$ 0.001
Common stock, shares outstanding				22,369,393	21,667,250
Preferred stock, shares authorized				2,500,000	2,500,000
Preferred stock, par or stated value per share				$ 0.001	$ 0.001
Preferred stock, shares outstanding				1,060,873	1,120,873
Declared Dividend				$ 0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares converted	25,000	10,000	25,000
Conversion price	$ 5.75	$ 5.75	$ 5.75
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued in conversion	250	100	250
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized				1,850,000

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Offsetting Assets [Line Items]
Shares, Options outstanding at beginning of year	1,976,586	1,315,321
Weighted Average Exercise Price, Options outstanding at beginning of year	$ 6.34	$ 11.97
Shares, Granted	874,548	720,047
Weighted Average Exercise Price, Granted	$ 10.13	$ 7.19
Shares, Exercised	(82,708)	(4,660)
Weighted Average Exercise Price, Exercised	$ 3.65	$ 5.20
Shares, Forfeited	(65,797)	(111,594)
Weighted Average Exercise Price, Forfeited	$ 7.45	$ 10.86
Shares, Options outstanding at end of year	2,702,629	1,919,114
Weighted Average Exercise Price, Options outstanding at end of year	$ 7.63	$ 6.08
Shares, options exercisable	1,440,231	882,215
Weighted Average Exercise Price, Options exercisable	$ 6.26	$ 5.92
Weighted Average Grant Date Fair Value for options granted during the period	$ 7.09	$ 4.87

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding and Exercisable (Details) - Share-Based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding | shares	2,702,629
Options outstanding, weighted average remaining contractual life	8 years 1 month 2 days
Options outstanding, weighted average exercise price | $ / shares	$ 7.63
Options outstanding, aggregate intrinsic value | $	$ 5,355,467
Options exercisable | shares	1,440,231
Options exercisable, weighted average exercise price | $ / shares	$ 6.26
Options exercisable, aggregate intrinsic value | $	$ 4,470,641

Schedule of Assumptions for Fai

Schedule of Assumptions for Fair Value of Equity-based Awards (Details)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	3.41%	1.68%
Risk-free interest rate maximum	4.61%	3.93%
Expected volatility, minimum	78%	76.20%
Expected volatility, maximum	79.80%	79.60%
Expected dividend yield	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (years)	5 years 3 months	5 years 3 months 14 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected life (years)	6 years 29 days	6 years 3 months

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Cost (Details)	Sep. 30, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
2023	$ 1,177,419
2024	3,679,163
2025	2,465,972
2026	1,515,642
2027	635,575
Total estimated compensation cost to be recognized	$ 9,473,771

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,108,637	$ 1,223,054	$ 3,658,902	$ 3,498,784
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	660,706	676,524	1,954,689	1,937,707
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 447,931	$ 546,530	$ 1,704,213	$ 1,561,077

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended
	May 12, 2022	May 12, 2021	May 10, 2018	Oct. 25, 2017	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	May 11, 2023	Jan. 01, 2023	May 31, 2022	Jan. 01, 2022	Dec. 31, 2021	Jan. 01, 2021	May 31, 2020
May 2022 Exercise Price Modification [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option awards shares modified											776,324
Stock option exercise price per share											$ 5.50
Modification on stock-based compensation					$ 30,188	$ 49,088	$ 107,490	$ 477,431
Remaining stock based compensation expense related to modification							190,000
December 2021 Exercise Price Modification [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option awards shares modified													311,000
Stock option exercise price per share													$ 13.44
Modification on stock-based compensation					15,773	21,778	49,617	75,562
Remaining stock based compensation expense related to modification							114,000
May 2020 Exercise Price Modification [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option awards shares modified															203,750
Stock option exercise price per share															$ 5.10
Modification on stock-based compensation					$ 3,041	7,681	16,975	30,897
Remaining stock based compensation expense related to modification							$ 3,000
2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, shares reserved for issuance	1,000,000	1,000,000		750,000					1,500,000	216,673		149,189		102,998
Stock option description				increase automatically on January 1 of each year from 2024 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31, subject to the board’s discretion to reduce the amount of the increase in any particular year.
Additional shares authorized under plan	500,000	500,000
Shares available for issuance					1,147,899		1,147,899
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Recognized stock-based compensation expense					$ 1,065,568	1,162,751	$ 3,516,180	3,329,969
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Recognized stock-based compensation expense					$ 4,903	$ 7,245	$ 13,597	$ 36,686
Restricted stock awards outstanding					1,958	3,273	1,958	3,273
Restricted stock awards vested					0	250
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Recognized stock-based compensation expense					$ 38,167	$ 53,058	$ 129,125	$ 132,129
Common stock, shares reserved for issuance			100,000
Stock option description			number of shares equal to 0.5% of the total outstanding number of shares of Company common stock as of the immediately preceding December 31.
Shares available for issuance					283,008		283,008
Change in common stock, shares reserved for issuance										108,337		74,594		51,499

Schedule of Long-term Debt (Det

Schedule of Long-term Debt (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Note payable	$ 35,000,000	$ 35,000,000
Add: PIK interest (added to principal)	2,100,835	755,075
Less: unamortized debt issuance costs	(540,392)	(707,001)
Less: unamortized debt discount	(53,669)	(65,000)
Total long-term debt	$ 36,506,774	$ 34,983,074

Schedule of Long Term Debt Futu

Schedule of Long Term Debt Future Principal Payments (Details)	Sep. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2025	$ 13,912,813
2026	18,550,418
2027	4,637,604
Total	$ 37,100,835

Debt (Details Narrative)

Debt (Details Narrative) - Innovatus Life Sciences [Member] - USD ($) $ in Millions	Sep. 30, 2023	Dec. 22, 2022	Aug. 09, 2022	Apr. 08, 2021
Amended Loan Agreement [Member]
Short-Term Debt [Line Items]
Funded contingent loan, outstanding	$ 35
Amended Loan Agreement [Member] | Term A Loan [Member]
Short-Term Debt [Line Items]
Non-contingent loan, amount				$ 15
Amended Loan Agreement [Member] | Term B Loan [Member]
Short-Term Debt [Line Items]
Non-contingent loan, amount		$ 20
Amended Loan Agreement [Member]
Short-Term Debt [Line Items]
Unfunded contingent maximum loan, amount			$ 75
Increase from original loan amount			$ 50

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	Oct. 18, 2023	Oct. 13, 2023	Sep. 21, 2023	Jun. 29, 2023	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Common stock, par value						$ 0.001	$ 0.001
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares converted			25,000	10,000	25,000
Conversion price			$ 5.75	$ 5.75	$ 5.75
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued in conversion			250	100	250
Subsequent Event [Member]
Subsequent Event [Line Items]
Share price	$ 8.699
Warrant exercise price	$ 0.001
Gross proceeds	$ 50
Percentage of liquidated damages	100%
Subsequent Event [Member] | Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares converted		181,739
Conversion price	$ 5.75
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued in conversion		1,817,390
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage of liquidated damages	600%
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Pre-funded warrants to purchase of common stock, shares	5,747,787
Common stock, par value	$ 0.001